Oxybutynin Chloride
Product Images NDC 10135-609
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 10135-609). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Marlex Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Mean R-oxybutynin Plasma Concentrations Following A Single Dose Of Oxybutynin Chloride 10 mg And Oxybutynin 5 mg Administered Every 8 Hours (n=23 For Each Treatment). (Oxybutynin Chloride 02)
The Structural Formula Of Mean Steady-state (± Sd) R-oxybutynin Plasma Concentrations Following Administration Of 5 To 20 mg Oxybutynin Chloride Once Daily In Children Aged 5 To 15. Plot Represents All Available Data Normalized To An Equivalent Of Oxybutynin Chloride 5 mg Once Daily. (Oxybutynin Chloride 03)
Mean Change (sd) In Episodes Per Week From Baseline (Oxybutynin Chloride 04)
Mean Change (sd) In Episodes Per Week From Baseline (Oxybutynin Chloride 05)
Mean Change (sd) In Episodes Per Week From Baseline (Oxybutynin Chloride 06)
Principal Display Panelndc 10135-0609-01marlexoxybutynin Chlorideextended- Releasetablets, Usp5 mgrx Only100 Tablets (Oxybutynin Chloride 07)
This is a description of a medication called Oxybutynin Chloride Extended-Release Tablets, USP which is manufactured and distributed by Marlex Pharmaceuticals. It comes in a package of 100 tablets with each extended-release tablet containing 5mg of oxybutynin chloride. The usual dosage information can be found in the package insert. It needs to be stored at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F) to maintain controlled room temperature. It should be protected from moisture and humidity. Made in the USA.*
Principal Display Panelndc 10135-0609-05marlexoxybutynin Chlorideextended- Releasetablets, Usp5 mgrx Only500 Tablets (Oxybutynin Chloride 08)
This is a description of a medication with the NDC number 10135-0609-05. The medication contains 5mg of oxybutynin chloride in a controlled-release formulation. The usual dosage and other relevant information are included in the package insert. The medication is to be stored at 20° to 25°C and protected from moisture and humidity. It is manufactured and distributed by Marlex Pharmaceuticals, Inc. in New Castle, DE and is made in the USA. There are 500 tablets in the container and the price is not available.*
Principal Display Panelndc 10135-0610-01marlexoxybutynin Chlorideextended- Releasetablets, Usp10 mgrx Only100 Tablets (Oxybutynin Chloride 09)
This is a medication with NDC 10135-0610-01 used to treat urinary incontinence. Each extended-release tablet contains 10mg of oxybutynin chloride USP in a controlled-release formulation. It is manufactured and distributed by Marlex Pharmaceuticals, Inc. Dosage information can be found in the package insert. The tablets should be stored in a dry place at room temperature, protected from moisture and humidity.*
Principal Display Panelndc 10135-0610-05marlexoxybutynin Chlorideextended- Releasetablets, Usp10 mgrx Only500 Tablets (Oxybutynin Chloride 0a)
Each tablet contains 10 mg of oxybutynin chloride, USP in a controlled-release formulation. See package insert for dosage information. The tablets should be stored at a temperature of 20° to 25°C (68° to 77°F) to avoid moisture and humidity. The medication is manufactured and distributed by Marlex Pharmaceuticals, Inc. in New Castle, DE 19720. This medication is available by prescription only and comes in a bottle of 500 tablets.*
Principal Display Panelndc 10135-0611-01marlexoxybutynin Chlorideextended- Releasetablets, Usp15 mgrx Only100 Tablets (Oxybutynin Chloride 0b)
This medication is Oxybutynin Chloride Extended-Release Tablet with 15mg strength. It is manufactured and distributed by Marlex Pharmaceuticals, Inc. with the prescription of a physician. The medication is for oral use only, and each tablet contains 15mg of oxybutynin. Patients must follow the instructions in the package insert for the appropriate dosage. Store this medication at a temperature between 20°C to 25°C, with permitted excursions to 15°C to 30°C, and protect from moisture and humidity. The medication is made in the USA.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.